Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Recommendation of “Hold” from Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN) has been given a consensus rating of “Hold” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.9250.

A number of equities analysts have commented on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Canaccord Genuity Group reduced their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Finally, Wall Street Zen downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th.

Smith & Nephew SNATS Stock Up 1.7%

Shares of SNN stock opened at $30.83 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The firm’s 50-day moving average is $32.07 and its two-hundred day moving average is $33.28. Smith & Nephew SNATS has a 12 month low of $28.23 and a 12 month high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last issued its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The firm had revenue of $1.60 billion for the quarter. Equities research analysts anticipate that Smith & Nephew SNATS will post 2.25 EPS for the current fiscal year.

Smith & Nephew SNATS Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be paid a dividend of $0.482 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a yield of 304.0%.

Hedge Funds Weigh In On Smith & Nephew SNATS

Institutional investors have recently bought and sold shares of the company. Garner Asset Management Corp purchased a new stake in shares of Smith & Nephew SNATS in the 4th quarter valued at approximately $27,000. Arax Advisory Partners raised its stake in shares of Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 569 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Smith & Nephew SNATS in the 4th quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS in the 3rd quarter valued at approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Smith & Nephew SNATS in the 4th quarter valued at approximately $43,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.